Veradermics
About Veradermics
Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on turning everyday dermatology and aesthetics problems into clear, proven care. The company is developing novel therapeutics for common skin and hair conditions, with a lead candidate, VDPHL01, potentially the first non-hormonal oral treatment for hair regrowth in women and men. Headquartered in New Haven, Connecticut, they pursue clinical development and translational research to address underserved dermatology needs.
Recent News
STAT+: A Sign Biotech Is Back? Four Drugmakers Go Public, Raising Nearly $1 Billion in All
Will the Iran Truce Hold? Where to Invest—Whether It Fizzles or Settles In
JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return
Apple Gaining Market Share In PCs, Smartphones
Eikon Prices Its IPO, Seeking to Raise $318m
Oral Rogaine Maker Veradermics Looks to Raise $181M From IPO
2026 IPO Train Keeps Chugging as AgomAb, SpyGlass Eye Nasdaq Debut
Hair Growth Biotech Veradermics Files for IPO to Fund Oral Rogaine
Veradermics CEO Has a Great Hair Day with 122% Pop in IPO
Three More Biotechs Price Their Nasdaq IPOs
